Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • RB-PDT for Fusarium Keratitis: The LUMIERE Study

    NCT07743489 · start 2027-01

    Registered record
    Registry ID
    NCT07743489
    Conditions
    Fusarium Keratitis
    Interventions
    Rose Bengal Photodynamic Therapy; Sham RB-PDT
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-01
    Completion
    2030-01
    Enrolment
    434

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFusarium Keratitis
    InterventionRose Bengal Photodynamic Therapy; Sham RB-PDT
    PhasePhase 3
    Registry statusNot yet recruiting

  • Finerenone for AKI: a Multicenter, Randomized, Placebo-Controlled Feasibility Pilot Trial

    NCT07775482 · start 2027-01

    Registered record
    Registry ID
    NCT07775482
    Conditions
    Acute Kidney Injury; Renal Insufficiency,Chronic; Kidney Diseases
    Interventions
    Finerenone (BAY94-8862 ) 10 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2027-01
    Completion
    2030-01
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Kidney Injury; Renal Insufficiency,Chronic; Kidney Diseases
    InterventionFinerenone (BAY94-8862 ) 10 mg; Placebo
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Magnetic Sentinel Lymph Node Mapping in Gastric Cancer

    NCT05038098 · start 2026-12-31

    Registered record
    Registry ID
    NCT05038098
    Conditions
    Gastric Adenocarcinoma
    Interventions
    Gastrectomy; Indocyanine Green; Iron Conjugated Polymers in Saline Suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2027-02-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Adenocarcinoma
    InterventionGastrectomy; Indocyanine Green; Iron Conjugated Polymers in Saline Suspension
    PhasePhase 1
    Registry statusNot yet recruiting

  • An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

    NCT05477953 · start 2026-12-31

    Registered record
    Registry ID
    NCT05477953
    Conditions
    Chagas Disease
    Interventions
    Nifurtimox (BAYA2502)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2032-01-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionNifurtimox (BAYA2502)
    PhaseNot recorded
    Registry statusNot yet recruiting

  • NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

    NCT07261241 · start 2026-12-31

    Registered record
    Registry ID
    NCT07261241
    Conditions
    Neuroblastoma
    Interventions
    Radiation: 131I-MIBG; Dinutuximab; Vorinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2031-12-31
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma
    InterventionRadiation: 131I-MIBG; Dinutuximab; Vorinostat
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia

    NCT07674810 · start 2026-12-31

    Registered record
    Registry ID
    NCT07674810
    Conditions
    Chronic Lymphocytic Leukemia
    Interventions
    Zanubrutinib; Obinutuzumab; Sonrotoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2029-04-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia
    InterventionZanubrutinib; Obinutuzumab; Sonrotoclax
    PhasePhase 2
    Registry statusNot yet recruiting

  • Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

    NCT07704918 · start 2026-12-31

    Registered record
    Registry ID
    NCT07704918
    Conditions
    Melanoma
    Interventions
    Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-12-31
    Completion
    2028-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionStatins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
    PhaseNot applicable
    Registry statusRecruiting

  • Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers

    NCT07791199 · start 2026-12-31

    Registered record
    Registry ID
    NCT07791199
    Conditions
    Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis; Psoriatic Arthritis
    Interventions
    Deucravacitinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2030-10-31
    Enrolment
    2,300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus; Sjögren's Disease; Psoriasis; Psoriatic Arthritis
    InterventionDeucravacitinib
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer

    NCT07796100 · start 2026-12-31

    Registered record
    Registry ID
    NCT07796100
    Conditions
    Extensive-Stage Small Cell Lung Cancer
    Interventions
    ZL-1310 in combination with Atezolizumab or Durvalumab; Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin; Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2031-06-30
    Enrolment
    530

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-Stage Small Cell Lung Cancer
    InterventionZL-1310 in combination with Atezolizumab or Durvalumab; Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin; Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance
    PhasePhase 3
    Registry statusNot yet recruiting

  • Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    NCT07582159 · start 2026-12-19

    Registered record
    Registry ID
    NCT07582159
    Conditions
    Chronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma
    Interventions
    Acalabrutinib; Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Positron Emission Tomography; Tafasitamab; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-19
    Completion
    2029-04-14
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Small Lymphocytic Lymphoma
    InterventionAcalabrutinib; Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography +3 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Minocycline In Neurocognitive Outcomes - Sickle Cell Disease

    NCT05605366 · start 2026-12-01

    Registered record
    Registry ID
    NCT05605366
    Conditions
    Sickle Cell Disease; Cognitive Impairment; Cognitive Decline; Cognitive Change; Cognitive Dysfunction; Cognitive Deficit; Neuroinflammatory Response
    Interventions
    Minocycline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2028-06-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease; Cognitive Impairment; Cognitive Decline; Cognitive Change +3 more
    InterventionMinocycline; Placebo
    PhasePhase 1
    Registry statusNot yet recruiting

  • Investigating Novel Interventions for Low Back Pain in US Military Veterans: A Randomized Controlled Adaptive Phase II Trial

    NCT05935761 · start 2026-12-01

    Registered record
    Registry ID
    NCT05935761
    Conditions
    Chronic Low Back Pain
    Interventions
    Pregnenolone; DHEA; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-12-31
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Low Back Pain
    InterventionPregnenolone; DHEA; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis

    NCT06228781 · start 2026-12-01

    Registered record
    Registry ID
    NCT06228781
    Conditions
    Multiple Sclerosis
    Interventions
    Autologous haemopoietic stem cell transplantation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-01-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionAutologous haemopoietic stem cell transplantation
    PhaseNot applicable
    Registry statusNot yet recruiting

  • VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

    NCT06320951 · start 2026-12-01

    Registered record
    Registry ID
    NCT06320951
    Conditions
    Cardiovascular Diseases; Insulin Sensitivity/Resistance; Metabolic Disease; Metabolism; Energy Expenditure; Obesity
    Interventions
    Vericiguat 10 MG; Placebo; Insulin Sensitivity Test; Resting Energy and Exercise Energy Expenditure Assessment; White Adipose Tissue Biopsy; MRI-PET Scan for Brown Adipose Tissue Volume Assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-04-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Insulin Sensitivity/Resistance; Metabolic Disease; Metabolism +2 more
    InterventionVericiguat 10 MG; Placebo; Insulin Sensitivity Test; Resting Energy and Exercise Energy Expenditure Assessment +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Oxfendazole in Mild Parenchymal Brain Cysticercosis

    NCT06565507 · start 2026-12-01

    Registered record
    Registry ID
    NCT06565507
    Conditions
    Brain Cysticercosis
    Interventions
    Oxfendazole single dose; Oxfendazole three doses; albendazole plus praziquantel regime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2030-12-15
    Enrolment
    544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Cysticercosis
    InterventionOxfendazole single dose; Oxfendazole three doses; albendazole plus praziquantel regime
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.